189 related articles for article (PubMed ID: 18656282)
1. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
Arulogun S; Prince HM; Gambell P; Lade S; Ryan G; Eaton E; McCormack C
J Am Acad Dermatol; 2008 Oct; 59(4):589-95. PubMed ID: 18656282
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution.
Bisaccia E; Gonzalez J; Palangio M; Schwartz J; Klainer AS
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):263-71. PubMed ID: 10906649
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
Schappell DL; Alper JC; McDonald CJ
Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
[TBL] [Abstract][Full Text] [Related]
4. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
[TBL] [Abstract][Full Text] [Related]
5. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
[TBL] [Abstract][Full Text] [Related]
7. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
McGinnis KS; Ubriani R; Newton S; Junkins-Hopkins JM; Vittorio CC; Kim EJ; Wysocka M; Rook AH
Arch Dermatol; 2005 Sep; 141(9):1176-8. PubMed ID: 16172331
[No Abstract] [Full Text] [Related]
8. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations.
Rook AH; Prystowsky MB; Cassin M; Boufal M; Lessin SR
Arch Dermatol; 1991 Oct; 127(10):1535-40. PubMed ID: 1929461
[TBL] [Abstract][Full Text] [Related]
12. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
[No Abstract] [Full Text] [Related]
14. Photopheresis does not improve survival in Sézary syndrome patients with bone marrow involvement.
de Misa RF; Harto A; Azaña JM; Belmar P; Díez E; Ledo A
J Am Acad Dermatol; 2005 Jul; 53(1):171-2. PubMed ID: 15965446
[No Abstract] [Full Text] [Related]
15. Extracorporeal photopheresis in Sézary syndrome.
Russell-Jones R; Fraser-Andrews E; Spittle M; Whittaker S
Lancet; 1997 Sep; 350(9081):886. PubMed ID: 9310623
[No Abstract] [Full Text] [Related]
16. [Sézary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate].
Hirayama Y; Nagai T; Ohta H; Koyama R; Matsunaga T; Sakamaki S; Niitsu Y
Rinsho Ketsueki; 2000 Sep; 41(9):750-4. PubMed ID: 11070938
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Bagot M
Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
[No Abstract] [Full Text] [Related]
19. Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases.
Schreiner T; Gaczkowski A; Scharffetter-Kochanek K; Borberg H
Transfus Apher Sci; 2005 Apr; 32(2):197-203. PubMed ID: 15784454
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.
Fraser-Andrews E; Seed P; Whittaker S; Russell-Jones R
Arch Dermatol; 1998 Aug; 134(8):1001-5. PubMed ID: 9722731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
